<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<article xml:lang="KO" article-type="case-report">

<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Korean Ophthalmol Soc</journal-id>
<journal-id journal-id-type="publisher-id">JKOS</journal-id>
<journal-title>Journal of the Korean Ophthalmological Society</journal-title>
<issn pub-type="ppub">0378-6471</issn>
<issn pub-type="epub">2092-9374</issn>
<publisher>
<publisher-name>The Korean Ophthalmological Society</publisher-name>
</publisher>
</journal-meta>

<article-meta>
<article-id pub-id-type="doi">10.3341/jkos.2012.53.5.721</article-id>
<article-categories>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Three Cases of Rituximab Treatment for Orbital Inflammatory Disease</article-title>
</title-group>

<contrib-group>

<contrib contrib-type="author">
<name>
<surname>Park</surname>
<given-names>Byung-Chun</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Woo</surname>
<given-names>Kyung-In</given-names>
</name>
<degrees>MD</degrees>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>

<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kim</surname>
<given-names>Yoon-Duck</given-names>
</name>
<degrees>MD</degrees>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>

</contrib-group>

<aff id="A1"><label>1</label>Department of Ophthalmology, Dongkang Medical Center, Ulsan, Korea.</aff>
<aff id="A2"><label>2</label>Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff>

<author-notes>
<corresp>Address reprint requests to Yoon-Duck Kim, MD, PhD. Department of Ophthalmology, Sungkyunkwan University Samsung Medical Center, #81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-3570, Fax: 82-2-3410-0074, <email>ydkimoph@skku.edu</email></corresp>
</author-notes>

<pub-date pub-type="ppub">
<month>05</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>05</month>
<year>2012</year>
</pub-date>
<volume>53</volume>
<issue>5</issue>
<fpage>721</fpage>
<lpage>727</lpage>
<history>
<date date-type="received">
<day>04</day>
<month>05</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>03</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2012 The Korean Ophthalmological Society</copyright-statement>
<copyright-year>2012</copyright-year>
</permissions>

<abstract>
<sec>
<title>Purpose</title>
<p>To report three cases of rituximab treatment in refractory orbital inflammatory disease.</p>
</sec>
<sec>
<title>Case summary</title>
<p>Rituximab treatment was performed in three patients (thyroid-associated ophthalmopathy, orbital myositis, and idiopathic sclerosing inflammation) unresponsive to corticosteroid and radiotherapy. One cycle consisted of intravenous infusion of 1000 mg of rituximab, twice at a two-week interval. The patient with thyroid-associated ophthalmopathy exhibited clinical improvement in visual acuity, color vision, visual evoked potential, and visual field after one cycle of rituximab treatment. The patient with orbital myositis improved showed diplopia with a decrease in the size of the extraocular muscle after two cycles of treatment. The patient with idiopathic sclerosing inflammation showed improvements in visual acuity and visual field defect after one cycle of therapy. There were no severe infections or hematologic adverse effects including neutropenia, or decreased immunoglobulin during the follow-up period.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Treatment with rituximab appears to offer another therapeutic option in patients unresponsive to corticosteroid or radiotherapy.</p>
</sec>
</abstract>

<kwd-group>
<kwd>Inflammation</kwd>
<kwd>Orbit</kwd>
<kwd>Rituximab</kwd>
<kwd>Thyoid</kwd>
</kwd-group>

</article-meta>
</front>

<back>

    <ref-list>
  <ref id="B1">
    <label>1</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Lutt</surname>
          <given-names>JR</given-names>
        </name>
        <name>
          <surname>Lim</surname>
          <given-names>LL</given-names>
        </name>
        <name>
          <surname>Phal</surname>
          <given-names>PM</given-names>
        </name>
        <name>
          <surname>Rosenbaum</surname>
          <given-names>JT</given-names>
        </name>
      </person-group>
      <article-title>Orbital inflammatory disease</article-title>
      <source>Semin Arthritis Rheum</source>
      <year>2008</year>
      <volume>37</volume>
      <fpage>207</fpage>
      <lpage>222</lpage>
    </nlm-citation>
  </ref>

  <ref id="B2">
    <label>2</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Tsokos</surname>
          <given-names>GC</given-names>
        </name>
      </person-group>
      <article-title>B cells, be gone--B-cell depletion in the treatment of rheumatoid arthritis</article-title>
      <source>N Engl J Med</source>
      <year>2004</year>
      <volume>350</volume>
      <fpage>2546</fpage>
      <lpage>2548</lpage>
    </nlm-citation>
  </ref>

  <ref id="B3">
    <label>3</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Pescovitz</surname>
          <given-names>MD</given-names>
        </name>
      </person-group>
      <article-title>Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action</article-title>
      <source>Am J Transplant</source>
      <year>2006</year>
      <volume>6</volume>
      <issue>5 Pt 1</issue>
      <fpage>859</fpage>
      <lpage>866</lpage>
    </nlm-citation>
  </ref>

  <ref id="B4">
    <label>4</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Smolen</surname>
          <given-names>JS</given-names>
        </name>
        <name>
          <surname>Keystone</surname>
          <given-names>EC</given-names>
        </name>
        <name>
          <surname>Emery</surname>
          <given-names>P</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Consensus statement on the use of rituximab in patients with rheumatoid arthritis</article-title>
      <source>Ann Rheum Dis</source>
      <year>2007</year>
      <volume>66</volume>
      <fpage>143</fpage>
      <lpage>150</lpage>
    </nlm-citation>
  </ref>

  <ref id="B5">
    <label>5</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>El Fassi</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Nielsen</surname>
          <given-names>CH</given-names>
        </name>
        <name>
          <surname>Hasselbalch</surname>
          <given-names>HC</given-names>
        </name>
        <name>
          <surname>Hegedus</surname>
          <given-names>L</given-names>
        </name>
      </person-group>
      <article-title>The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option</article-title>
      <source>Eur J Endocrinol</source>
      <year>2006</year>
      <volume>154</volume>
      <fpage>623</fpage>
      <lpage>632</lpage>
    </nlm-citation>
  </ref>

  <ref id="B6">
    <label>6</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Kurz</surname>
          <given-names>PA</given-names>
        </name>
        <name>
          <surname>Suhler</surname>
          <given-names>EB</given-names>
        </name>
        <name>
          <surname>Choi</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Rosenbaum</surname>
          <given-names>JT</given-names>
        </name>
      </person-group>
      <article-title>Rituximab for treatment of ocular inflammatory disease: a series of four cases</article-title>
      <source>Br J Ophthalmol</source>
      <year>2009</year>
      <volume>93</volume>
      <fpage>546</fpage>
      <lpage>548</lpage>
    </nlm-citation>
  </ref>

  <ref id="B7">
    <label>7</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Harris</surname>
          <given-names>GJ</given-names>
        </name>
      </person-group>
      <article-title>Idiopathic orbital inflammation: a pathogenetic construct and treatment strategy: The 2005 ASOPRS Foundation Lecture</article-title>
      <source>Ophthal Plast Reconstr Surg</source>
      <year>2006</year>
      <volume>22</volume>
      <fpage>79</fpage>
      <lpage>86</lpage>
    </nlm-citation>
  </ref>

  <ref id="B8">
    <label>8</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Yuen</surname>
          <given-names>SJ</given-names>
        </name>
        <name>
          <surname>Rubin</surname>
          <given-names>PA</given-names>
        </name>
      </person-group>
      <article-title>Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome</article-title>
      <source>Arch Ophthalmol</source>
      <year>2003</year>
      <volume>121</volume>
      <fpage>491</fpage>
      <lpage>499</lpage>
    </nlm-citation>
  </ref>

  <ref id="B9">
    <label>9</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Rubin</surname>
          <given-names>PA</given-names>
        </name>
        <name>
          <surname>Foster</surname>
          <given-names>CS</given-names>
        </name>
      </person-group>
      <article-title>Etiology and management of idiopathic orbital inflammation</article-title>
      <source>Am J Ophthalmol</source>
      <year>2004</year>
      <volume>138</volume>
      <fpage>1041</fpage>
      <lpage>1043</lpage>
    </nlm-citation>
  </ref>

  <ref id="B10">
    <label>10</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Hougardy</surname>
          <given-names>DM</given-names>
        </name>
        <name>
          <surname>Peterson</surname>
          <given-names>GM</given-names>
        </name>
        <name>
          <surname>Bleasel</surname>
          <given-names>MD</given-names>
        </name>
        <name>
          <surname>Randall</surname>
          <given-names>CT</given-names>
        </name>
      </person-group>
      <article-title>Is enough attention being given to the adverse effects of corticosteroid therapy?</article-title>
      <source>J Clin Pharm Ther</source>
      <year>2000</year>
      <volume>25</volume>
      <fpage>227</fpage>
      <lpage>234</lpage>
    </nlm-citation>
  </ref>

  <ref id="B11">
    <label>11</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Silkiss</surname>
          <given-names>RZ</given-names>
        </name>
        <name>
          <surname>Reier</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Coleman</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Lauer</surname>
          <given-names>SA</given-names>
        </name>
      </person-group>
      <article-title>Rituximab for thyroid eye disease</article-title>
      <source>Ophthal Plast Reconstr Surg</source>
      <year>2010</year>
      <volume>26</volume>
      <fpage>310</fpage>
      <lpage>314</lpage>
    </nlm-citation>
  </ref>

  <ref id="B12">
    <label>12</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Kazlow Stern</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Tripp</surname>
          <given-names>JM</given-names>
        </name>
        <name>
          <surname>Ho</surname>
          <given-names>VC</given-names>
        </name>
        <name>
          <surname>Lebwohl</surname>
          <given-names>M</given-names>
        </name>
      </person-group>
      <article-title>The use of systemic immune moderators in dermatology: an update</article-title>
      <source>Dermatol Clin</source>
      <year>2005</year>
      <volume>23</volume>
      <fpage>259</fpage>
      <lpage>300</lpage>
    </nlm-citation>
  </ref>

  <ref id="B13">
    <label>13</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Nash</surname>
          <given-names>PT</given-names>
        </name>
        <name>
          <surname>Florin</surname>
          <given-names>TH</given-names>
        </name>
      </person-group>
      <article-title>Tumour necrosis factor inhibitors</article-title>
      <source>Med J Aust</source>
      <year>2005</year>
      <volume>183</volume>
      <fpage>205</fpage>
      <lpage>208</lpage>
    </nlm-citation>
  </ref>

  <ref id="B14">
    <label>14</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Ho</surname>
          <given-names>VH</given-names>
        </name>
        <name>
          <surname>Chevez-Barrios</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Jorgensen</surname>
          <given-names>JL</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Receptor expression in orbital inflammatory syndromes and implications for targeted therapy</article-title>
      <source>Tissue Antigens</source>
      <year>2007</year>
      <volume>70</volume>
      <fpage>105</fpage>
      <lpage>109</lpage>
    </nlm-citation>
  </ref>

  <ref id="B15">
    <label>15</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Nielsen</surname>
          <given-names>CH</given-names>
        </name>
        <name>
          <surname>El Fassi</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Hasselbalch</surname>
          <given-names>HC</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family</article-title>
      <source>Expert Opin Biol Ther</source>
      <year>2007</year>
      <volume>7</volume>
      <fpage>1061</fpage>
      <lpage>1078</lpage>
    </nlm-citation>
  </ref>

  <ref id="B16">
    <label>16</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Takemura</surname>
          <given-names>S</given-names>
        </name>
        <name>
          <surname>Klimiuk</surname>
          <given-names>PA</given-names>
        </name>
        <name>
          <surname>Braun</surname>
          <given-names>A</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>T cell activation in rheumatoid synovium is B cell dependent</article-title>
      <source>J Immunol</source>
      <year>2001</year>
      <volume>167</volume>
      <fpage>4710</fpage>
      <lpage>4718</lpage>
    </nlm-citation>
  </ref>

  <ref id="B17">
    <label>17</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Vos</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>Thurlings</surname>
          <given-names>RM</given-names>
        </name>
        <name>
          <surname>Wijbrandts</surname>
          <given-names>CA</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis</article-title>
      <source>Arthritis Rheum</source>
      <year>2007</year>
      <volume>56</volume>
      <fpage>772</fpage>
      <lpage>778</lpage>
    </nlm-citation>
  </ref>

  <ref id="B18">
    <label>18</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Hasselbalch</surname>
          <given-names>HC</given-names>
        </name>
      </person-group>
      <article-title>B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis</article-title>
      <source>Immunol Lett</source>
      <year>2003</year>
      <volume>88</volume>
      <fpage>85</fpage>
      <lpage>86</lpage>
    </nlm-citation>
  </ref>

  <ref id="B19">
    <label>19</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Salvi</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Vannucchi</surname>
          <given-names>G</given-names>
        </name>
        <name>
          <surname>Campi</surname>
          <given-names>I</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression</article-title>
      <source>Eur J Endocrinol</source>
      <year>2006</year>
      <volume>154</volume>
      <fpage>511</fpage>
      <lpage>517</lpage>
    </nlm-citation>
  </ref>

  <ref id="B20">
    <label>20</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Salvi</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Vannucchi</surname>
          <given-names>G</given-names>
        </name>
        <name>
          <surname>Campi</surname>
          <given-names>I</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study</article-title>
      <source>Eur J Endocrinol</source>
      <year>2007</year>
      <volume>156</volume>
      <fpage>33</fpage>
      <lpage>40</lpage>
    </nlm-citation>
  </ref>

  <ref id="B21">
    <label>21</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Khanna</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Chong</surname>
          <given-names>KK</given-names>
        </name>
        <name>
          <surname>Afifiyan</surname>
          <given-names>NF</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy</article-title>
      <source>Ophthalmology</source>
      <year>2010</year>
      <volume>117</volume>
      <fpage>133</fpage>
      <lpage>139.e2</lpage>
    </nlm-citation>
  </ref>

  <ref id="B22">
    <label>22</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>El Fassi</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Banga</surname>
          <given-names>JP</given-names>
        </name>
        <name>
          <surname>Gilbert</surname>
          <given-names>JA</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies</article-title>
      <source>Clin Immunol</source>
      <year>2009</year>
      <volume>130</volume>
      <fpage>252</fpage>
      <lpage>258</lpage>
    </nlm-citation>
  </ref>

  <ref id="B23">
    <label>23</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Schafranski</surname>
          <given-names>MD</given-names>
        </name>
      </person-group>
      <article-title>Idiopathic orbital inflammatory disease successfully treated with rituximab</article-title>
      <source>Clin Rheumatol</source>
      <year>2009</year>
      <volume>28</volume>
      <fpage>225</fpage>
      <lpage>226</lpage>
    </nlm-citation>
  </ref>

  <ref id="B24">
    <label>24</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Smolen</surname>
          <given-names>JS</given-names>
        </name>
        <name>
          <surname>Keystone</surname>
          <given-names>EC</given-names>
        </name>
        <name>
          <surname>Emery</surname>
          <given-names>P</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Consensus statement on the use of rituximab in patients with rheumatoid arthritis</article-title>
      <source>Ann Rheum Dis</source>
      <year>2007</year>
      <volume>66</volume>
      <fpage>143</fpage>
      <lpage>150</lpage>
    </nlm-citation>
  </ref>

  <ref id="B25">
    <label>25</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Emery</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Fleischmann</surname>
          <given-names>R</given-names>
        </name>
        <name>
          <surname>Filipowicz-Sosnowska</surname>
          <given-names>A</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial</article-title>
      <source>Arthritis Rheum</source>
      <year>2006</year>
      <volume>54</volume>
      <fpage>1390</fpage>
      <lpage>1400</lpage>
    </nlm-citation>
  </ref>

  <ref id="B26">
    <label>26</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Edwards</surname>
          <given-names>JC</given-names>
        </name>
        <name>
          <surname>Szczepanski</surname>
          <given-names>L</given-names>
        </name>
        <name>
          <surname>Szechinski</surname>
          <given-names>J</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis</article-title>
      <source>N Engl J Med</source>
      <year>2004</year>
      <volume>350</volume>
      <fpage>2572</fpage>
      <lpage>2581</lpage>
    </nlm-citation>
  </ref>

  <ref id="B27">
    <label>27</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Dunleavy</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>Hakim</surname>
          <given-names>F</given-names>
        </name>
        <name>
          <surname>Kim</surname>
          <given-names>HK</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis</article-title>
      <source>Blood</source>
      <year>2005</year>
      <volume>106</volume>
      <fpage>795</fpage>
      <lpage>802</lpage>
    </nlm-citation>
  </ref>

  <ref id="B28">
    <label>28</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Edwards</surname>
          <given-names>JC</given-names>
        </name>
        <name>
          <surname>Leandro</surname>
          <given-names>MJ</given-names>
        </name>
        <name>
          <surname>Cambridge</surname>
          <given-names>G</given-names>
        </name>
      </person-group>
      <article-title>B lymphocyte depletion therapy with rituximab in rheumatoid arthritis</article-title>
      <source>Rheum Dis Clin North Am</source>
      <year>2004</year>
      <volume>30</volume>
      <fpage>393</fpage>
      <lpage>403</lpage>
      <fpage>viii</fpage>
    </nlm-citation>
  </ref>

    </ref-list>

</back>

<floats-wrap>

<fig position="float" id="F1">
<label>Figure 1</label>
<caption>
  <p>Case 1. (A, C) Both eyes show conjunctival injection and proptosis. (B, D) Conjunctival injection in both eyes have markedly decreased after rituximab infusion. (E, G) Axial (E) and coronal (G) CT scans show marked fusiform enlargement of extraocular muscles in both sides. The coronal section shows compression of optic nerve in the orbital apex. (F, H) After rituximab infusion, apical crowding and stretching of optic nerve in the CT scan have improved. (I, J) Change in visual field before (I) and after (J) rituximab infusion.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jkos-53-721-g001" alt-version="no"></graphic>
</fig>

<fig position="float" id="F2">
<label>Figure 2</label>
<caption>
  <p>Case 2. (A, B) Proptosis and upper lid swelling of the left eye before rituximab infusion (A) decreased after therapy (B). (C, E) Coronal CT scans show enlargement of the left superior oblique and medial rectus before rituximab treatment. (D, F) After rituximab treatment, muscle enlargement markedly decreased.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jkos-53-721-g002" alt-version="no"></graphic>
</fig>

<fig position="float" id="F3">
<label>Figure 3</label>
<caption>
  <p>Case 3. (A, C) CT scans show infiltrative lobulated homogeneous mass in the left intraconal space. The optic nerve is involved by the orbital mass and displaced in the inferolateral direction. (B, D) After Rituximab infusion, orbital mass decreased and optic nerve infiltration improved.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jkos-53-721-g003" alt-version="no"></graphic>
</fig>

</floats-wrap>

</article>